This study, therefore, identifies ZNF674-AS1 as a crucial target for optimizing genotoxic drug therapy in NB patients and targeting ZNF674-AS1 may represent a potential treatment strategy for enhancing chemo-sensitization of anticancer drugs. Here, ZNF674 is linked to neuroblastoma.